<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Site da Brakke Consulting</provider_name><provider_url>https://brakkeconsulting.com/pt</provider_url><title>News from Brakke Consulting</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="XDikUlFz82"&gt;&lt;a href="https://brakkeconsulting.com/pt/20065/"&gt;Not&#xED;cias e notas de sa&#xFA;de animal de 10 de outubro de 2003&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://brakkeconsulting.com/pt/20065/embed/#?secret=XDikUlFz82" width="600" height="338" title="&#x201C;Not&#xED;cias e notas sobre sa&#xFA;de animal para 10 de outubro de 2003&#x201D; &#x2014; Site da Brakke Consulting" data-secret="XDikUlFz82" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://brakkeconsulting.com/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;</html><description>******************************************************************* Brakke Consulting&rsquo;s Animal Health News &amp; Notes for October 10, 2003 Copyright &copy; Brakke Consulting, Inc. ******************************************************************* You can now use this section to jump directly to a news item about a particular company.&nbsp; Simply click on the company name. &nbsp; JUMP TO: &nbsp; APEIS AgInfoLink Cargill Digital Angel eMerge Interactive Farmland IMI Global Merial Micro Beef Technologies Qiagen Smithfield Foods Swift &amp; Co (earnings) Veterinary Products Laboratories ******************************************************************* COMPANY EARNINGS RELEASES &nbsp; &gt;&nbsp; Swift &amp; Co. reported results for its first fiscal quarter 2004 ended August 24, 2003.&nbsp; Net sales rose 16% to $2.48 billion, while first-quarter earnings before interest, taxes, depreciation and amortization rose 87% to $95.2 million. The company&rsquo;s Swift Beef unit posted first-quarter operating income up 42% to $62.1 million, while Swift Pork posted a 187% rise in operating income to $14.7 million. (Meating Place) ******************************************************************* COMPANY NEWS RELEASES &nbsp; &gt;&nbsp; QIAGEN N.V. and Merial Limited announced that Merial has acquired the assets of QIAGEN&rsquo;s Pecura business acquired and developed by QIAGEN.&nbsp; The technology portfolio of the Pecura division includes the veterinary rights to a novel class of drugs that are based on immunostimulatory dinucleotides, which are believed to have promising potential in veterinary applications for livestock and companion animals. Pecura has an exclusive license from Coley Pharmaceutical Group, Inc. for the use of theView Full Post;</description></oembed>
